{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T13:40:02Z","timestamp":1717940402604},"reference-count":118,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.neurol.2015.04.005","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T03:30:38Z","timestamp":1434079838000},"page":"581-601","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["American Academy of Neurology, Washington, 18\u201325\u00a0avril\u00a02015"],"prefix":"10.1016","volume":"171","author":[{"given":"I.","family":"Sibon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"de Toffol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thomas-Ant\u00e9rion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"L\u00e9ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pierrot-Deseilligny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2015.04.005_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A randomized trial of intraarterial treatment for acute ischemic stroke","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2015.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1414905","article-title":"Randomized assessment of rapid endovascular treatment of ischemic stroke","volume":"372","author":"Goyal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2015.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa1414792","article-title":"Endovascular therapy for ischemic stroke with perfusion-imaging selection","volume":"372","author":"Campbell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2015.04.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1415061","article-title":"Stent-retriever thrombectomy after intravenous t-PA versus t-PA alone in stroke","author":"Saver","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2015.04.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1503780","article-title":"Thrombectomy within 8\u00a0hours after symptom onset in ischemic stroke","author":"Jovin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2015.04.005_bib0030","doi-asserted-by":"crossref","first-page":"P4.304","DOI":"10.1212\/WNL.84.14_supplement.P4.304","article-title":"Intra-arterial therapy is safe and effective in patients aged\u226580","volume":"84","author":"Frei","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0035","doi-asserted-by":"crossref","first-page":"P4.306","DOI":"10.1212\/WNL.84.14_supplement.P4.306","article-title":"Why are most stroke patients deemed poor candidates for intra-arterial therapy? A prospective study","volume":"84","author":"Damania","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0040","doi-asserted-by":"crossref","first-page":"S21.001","DOI":"10.1212\/WNL.84.14_supplement.S21.001","article-title":"Benefits of stroke treatment delivered using a mobile stroke unit","volume":"84","author":"Grotta","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0045","doi-asserted-by":"crossref","first-page":"S21.002","DOI":"10.1212\/WNL.84.14_supplement.S21.002","article-title":"Pre-hospital imaging and thrombolysis in acute stroke in an urban US setting: results of the Cleveland Pre-Hospital Acute Stroke Treatment (PHAST) study grup","volume":"84","author":"Briggs","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0050","doi-asserted-by":"crossref","first-page":"P4.310","DOI":"10.1212\/WNL.84.14_supplement.P4.310","article-title":"Early triage of acute ischemic stroke patients using mobile stroke unit shortens time to intra-arterial therapy","volume":"84","author":"Buletko","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2015.04.005_bib0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1474-4422(15)70018-9","article-title":"Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomized trial","volume":"14","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2015.04.005_bib0060","doi-asserted-by":"crossref","first-page":"P1.012","DOI":"10.1212\/WNL.84.14_supplement.P1.012","article-title":"Endovascular management and outcome of acute middle cerebral artery stroke in the setting of spontaneous carotid dissection","volume":"84","author":"Gulati","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0065","doi-asserted-by":"crossref","first-page":"P5.159","DOI":"10.1212\/WNL.84.14_supplement.P5.159","article-title":"Intraarterial thrombolysis and endovascular treatment is safe and effective in patients with ischemic stroke due to dissection","volume":"84","author":"Jensen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0070","doi-asserted-by":"crossref","first-page":"P5.160","DOI":"10.1212\/WNL.84.14_supplement.P5.160","article-title":"Outcome of acute ischemic stroke caused by cervicocephalic arterial dissection following intravenous thrombolysis and\/or endovascular treatment","volume":"84","author":"Ahmad","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0075","doi-asserted-by":"crossref","first-page":"P1.013","DOI":"10.1212\/WNL.84.14_supplement.P1.013","article-title":"Greater risk for decompressive craniectomy in large-artery strokes due to cervical artery","volume":"84","author":"Surakiatchanukul","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0080","doi-asserted-by":"crossref","first-page":"P1.002","DOI":"10.1212\/WNL.84.14_supplement.P1.002","article-title":"Collateral score and neurologic worsening in patients with carotid dissection","volume":"84","author":"Jia","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0085","doi-asserted-by":"crossref","first-page":"S5.005","DOI":"10.1212\/WNL.84.14_supplement.S5.005","article-title":"Body weight and survival after stroke: exploring the \u201cobesity paradox\u201d in the Framingham study","volume":"84","author":"Aparicio","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0090","doi-asserted-by":"crossref","first-page":"P3.071","DOI":"10.1212\/WNL.84.14_supplement.P3.071","article-title":"Effect of cigarette smoking on outcomes of acute ischemic stroke treated with intravenous thrombolysis: is there any paradox in the brain?","volume":"84","author":"Hussein","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0095","doi-asserted-by":"crossref","first-page":"P1.026","DOI":"10.1212\/WNL.84.14_supplement.P1.026","article-title":"Left ventricular noncompaction with normal heart function: a rare cause of cardioembolic stroke in a young adult","volume":"84","author":"Hainline","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0100","doi-asserted-by":"crossref","first-page":"P2.254","DOI":"10.1212\/WNL.84.14_supplement.P2.254","article-title":"Acute ischemic stroke due to left ventricular noncompaction syndrome from a novel mutation of the lamin A\/C gene","volume":"84","author":"Vongveeranonchai","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0105","doi-asserted-by":"crossref","first-page":"P1.003","DOI":"10.1212\/WNL.84.14_supplement.P1.003","article-title":"Susceptibility weighted imaging the of brain in infective endocarditis","volume":"84","author":"Schrag","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0110","doi-asserted-by":"crossref","first-page":"P1.053","DOI":"10.1212\/WNL.84.14_supplement.P1.053","article-title":"Paroxysmal atrial fibrillation detection rates in cryptogenic stroke patients selected by stroke specialists for prolonged cardiac monitoring","volume":"84","author":"Salahuddin","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0115","doi-asserted-by":"crossref","first-page":"P2.278","DOI":"10.1212\/WNL.84.14_supplement.P2.278","article-title":"The need for performance protocols for TEE and TCD in detection of right to feft shunts","volume":"84","author":"Frey","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0120","doi-asserted-by":"crossref","first-page":"S47.002","DOI":"10.1212\/WNL.84.14_supplement.S47.002","article-title":"Stroke after cardiac valve replacement: distribution, etiology, and risk factors","volume":"84","author":"Massaro","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0125","doi-asserted-by":"crossref","first-page":"S39.001","DOI":"10.1212\/WNL.84.14_supplement.S39.001","article-title":"Systemic inflammatory response syndrome during hospitalization for intracerebral hemorrhage drives poor functional outcome at discharge","volume":"84","author":"Boehme","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0130","doi-asserted-by":"crossref","first-page":"P3.105","DOI":"10.1212\/WNL.84.14_supplement.P3.105","article-title":"Global cerebral edema after subarachnoid hemorrhage is associated with a peripheral immune response","volume":"84","author":"Parsha","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0135","doi-asserted-by":"crossref","first-page":"P7.133","DOI":"10.1212\/WNL.84.14_supplement.P7.133","article-title":"Cognition and major depression after frontal and cerebellar stroke","volume":"84","author":"Dulay","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0140","doi-asserted-by":"crossref","first-page":"S39.007","DOI":"10.1212\/WNL.84.14_supplement.S39.007","article-title":"Depression equally common after intracerebral hemorrhage as it is after acute ischemic stroke","volume":"84","author":"Denny","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0145","doi-asserted-by":"crossref","first-page":"P7.132","DOI":"10.1212\/WNL.84.14_supplement.P7.132","article-title":"Selective serotonin reuptake inhibitors for prevention of post stroke depression: a meta-analysis","volume":"84","author":"Juangco","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0150","doi-asserted-by":"crossref","first-page":"S14.004","DOI":"10.1212\/WNL.84.14_supplement.S14.004","article-title":"The Epinet collaboration: do neurologists around the world agree with diagnosing epilepsy? Results of a multinational study","volume":"84","author":"Bergin","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0155","doi-asserted-by":"crossref","first-page":"S6.005","DOI":"10.1212\/WNL.84.14_supplement.S6.005","article-title":"The single seizure clinic model: does it work? Effects on wait-times and patient outcomes","volume":"84","author":"Syed","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0160","doi-asserted-by":"crossref","first-page":"S31.002","DOI":"10.1212\/WNL.84.14_supplement.S31.002","article-title":"Reducing severity of comorbid psychiatric symptoms in an epilepsy clinic using a collocation model: results of a pilot intervention","volume":"84","author":"Chen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0165","doi-asserted-by":"crossref","first-page":"S31.005","DOI":"10.1212\/WNL.84.14_supplement.S31.005","article-title":"Seizure outcome after switching antiepileptic drugs: a matched, prospective study","volume":"84","author":"Finamore","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0170","doi-asserted-by":"crossref","first-page":"P1.257","DOI":"10.1212\/WNL.84.14_supplement.P1.257","article-title":"Clobazam vs clonazepam for adults with epilepsy: long-term results from a UK primary care database","volume":"84","author":"Brodie","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0175","doi-asserted-by":"crossref","first-page":"P5.088","DOI":"10.1212\/WNL.84.14_supplement.P5.088","article-title":"Does status epilepticus per se cause cerebrospinal fluid pleocytosis in the absence of infection?","volume":"84","author":"Afshari","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0180","doi-asserted-by":"crossref","first-page":"P5.089","DOI":"10.1212\/WNL.84.14_supplement.P5.089","article-title":"Comparison of clinical and neuropsychiatric profiles of patients with intermittent PNES (iPNES) and non-epileptic psychogenic status (NEPS)","volume":"84","author":"Arora","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0185","doi-asserted-by":"crossref","first-page":"P6.294","DOI":"10.1212\/WNL.84.14_supplement.P6.294","article-title":"Epilepsy in the elderly: temporal lobe atrophy present in many cases of epilepsy of unknown etiology","volume":"84","author":"Lapointe","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0190","doi-asserted-by":"crossref","first-page":"P1.192","DOI":"10.1212\/WNL.84.14_supplement.P1.192","article-title":"A global long-term registry on efficacy and safety of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease in routine care (GLORIA): interim results in a subgroup of patients with dyskinesia at baseline","volume":"84","author":"Poewe","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0195","doi-asserted-by":"crossref","first-page":"P1.187","DOI":"10.1212\/WNL.84.14_supplement.P1.187","article-title":"Pharmacokinetics and safety of ND0612L (levodopa\/carbidopa for subcutaneous infusion): results from a phase\u00a0II study in moderate to severe Parkinson's disease","volume":"84","author":"Giladi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0200","doi-asserted-by":"crossref","first-page":"P1.184","DOI":"10.1212\/WNL.84.14_supplement.P1.184","article-title":"Summary of safety from clinical trial experience with IPX066, extended-release carbidopa-levodopa, in Parkinson's disease","volume":"84","author":"Mark","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0205","doi-asserted-by":"crossref","first-page":"P1.185","DOI":"10.1212\/WNL.84.14_supplement.P1.185","article-title":"Comparison of safety from phase\u00a03\u00a0clinical trials of IPX066, an extended-release carbidopa-levodopa formulation, in Parkinson's disease","volume":"84","author":"Dahll","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0210","doi-asserted-by":"crossref","first-page":"P1.188","DOI":"10.1212\/WNL.84.14_supplement.P1.188","article-title":"De-novo amantadine treatment delays onset of dyskinesias in patients with Parkinson disease","volume":"84","author":"Relja","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0215","doi-asserted-by":"crossref","first-page":"S7.003","DOI":"10.1212\/WNL.84.14_supplement.S7.003","article-title":"Glucocerebrosidase activity in Parkinson disease with and without GBA mutations","volume":"84","author":"Alcalay","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0220","doi-asserted-by":"crossref","first-page":"P2.149","DOI":"10.1212\/WNL.84.14_supplement.P2.149","article-title":"Peripheral \u03b2-glucocerebrosidase enzyme activity and lipidomics in \u00df-glucocerebrosidase (GBA1) mutation Parkinson disease","volume":"84","author":"Glickman","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0225","doi-asserted-by":"crossref","first-page":"S7.006","DOI":"10.1212\/WNL.84.14_supplement.S7.006","article-title":"Variants associated with Gaucher disease in multiple system atrophy","volume":"84","author":"Mitsui","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0230","doi-asserted-by":"crossref","first-page":"S7.002","DOI":"10.1212\/WNL.84.14_supplement.S7.002","article-title":"Phosphorylated pS1292\u00a0LRRK2\u00a0to total LRRK2\u00a0concentration ratio in urine exosomes distinguishes LRRK2-PD and idiopathic PD","volume":"84","author":"Alcalay","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0235","doi-asserted-by":"crossref","first-page":"P1.180","DOI":"10.1212\/WNL.84.14_supplement.P1.180","article-title":"A geographical cluster of progressive supranuclear palsy in Northern France","volume":"84","author":"Golbe","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0240","doi-asserted-by":"crossref","first-page":"P2.111","DOI":"10.1212\/WNL.84.14_supplement.P2.111","article-title":"Auto-immune cerebellar ataxia: treatment responses and outcomes in 118\u00a0patients","volume":"84","author":"Jones","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0245","doi-asserted-by":"crossref","first-page":"P5.297","DOI":"10.1212\/WNL.84.14_supplement.P5.297","article-title":"Therapeutic benefit of a HTT-lowering antisense oligonucleotide targeting the CAG-repeat in the R6\/2\u00a0Huntington's disease mouse model","volume":"84","author":"Datson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0250","doi-asserted-by":"crossref","first-page":"P2.127","DOI":"10.1212\/WNL.84.14_supplement.P2.127","article-title":"Holmes tremor, Etiology, associated symptoms, neuroimaging and treatment in a series of 20\u00a0cases","volume":"84","author":"Raina","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0255","doi-asserted-by":"crossref","first-page":"S15.002","DOI":"10.1212\/WNL.84.14_supplement.S15.002","article-title":"Can the mutant huntingtin gene product spread from cell to cell: evidence from neuronal allografts in Huntington's disease patients?","volume":"84","author":"Cicchetti","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0260","doi-asserted-by":"crossref","first-page":"P5.286","DOI":"10.1212\/WNL.84.14_supplement.P5.286","article-title":"Analysis of Parkinson's disease prodromal symptoms among Essential tremor subjects: is Essential tremor a risk factor for the development of Parkinson's disease?","volume":"84","author":"Salazar","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0265","doi-asserted-by":"crossref","first-page":"P5.279","DOI":"10.1212\/WNL.84.14_supplement.P5.279","article-title":"Unilateral focused ultrasound thalamotomy in Essential tremor: 3-year safety and efficacy data","volume":"84","author":"Shah","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0270","doi-asserted-by":"crossref","first-page":"P4.085","DOI":"10.1212\/WNL.84.14_supplement.P4.085","article-title":"Neuroimaging-based staging of pathological spread in patients with known pathology","volume":"84","author":"McMillan","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0275","doi-asserted-by":"crossref","first-page":"P1.225","DOI":"10.1212\/WNL.84.14_supplement.P1.225","article-title":"Eating behaviour and metabolic changes across the spectrum of motor neuron disease and frontotemporal dementia","volume":"84","author":"Ahmed","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0280","doi-asserted-by":"crossref","first-page":"P1-214","DOI":"10.1212\/WNL.84.14_supplement.P1.214","article-title":"The Neuropsychiatric Inventory Questionnaire (NPI-Q2): quantitative and qualitative between Alzheimer disease and frontotemporal dementia","volume":"84","author":"Hatfield","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0285","doi-asserted-by":"crossref","first-page":"S33-004","DOI":"10.1212\/WNL.84.14_supplement.S33.004","article-title":"Progranulin protein plasma and CSF levels in a large well-characterized dementia and healthy aging cohort","volume":"84","author":"Miller","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0290","doi-asserted-by":"crossref","first-page":"P2-160","DOI":"10.1212\/WNL.84.14_supplement.P2.160","article-title":"A novel splice site mutation in GRN (p.A237fs [A>T]) in a large Italian family with FTD from the Apullia-FTD registry","volume":"84","author":"Capozzo","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0295","doi-asserted-by":"crossref","first-page":"P2-175","DOI":"10.1212\/WNL.84.14_supplement.P2.175","article-title":"Clinical, neuropsychological and neuropathology characteristics of mixed dementia among subjects with autopsy confirmed concomitant Alzheimer's pathology","volume":"84","author":"Pillai","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0300","doi-asserted-by":"crossref","first-page":"P6-179","DOI":"10.1212\/WNL.84.14_supplement.P6.179","article-title":"Does DSM-5\u00a0change who gets diagnosed with Alzheimer disease, and who's checking?","volume":"84","author":"Shenker","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0305","doi-asserted-by":"crossref","first-page":"P2-168","DOI":"10.1212\/WNL.84.14_supplement.P2.168","article-title":"Semantic memory but not episodic memory is modulated by cognitive reserve in patients with MCI and AD","volume":"84","author":"Darby","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0310","doi-asserted-by":"crossref","first-page":"S41-002","DOI":"10.1212\/WNL.84.14_supplement.S41.002","article-title":"Variation in longevity gene KLOTHO is associated with greater cortical volumes in aging","volume":"84","author":"Yokoyama","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0315","doi-asserted-by":"crossref","first-page":"P1.213","DOI":"10.1212\/WNL.84.14_supplement.P1.213","article-title":"Cerebrospinal fluid biomarkers and [11C]Pittsburgh Compound-B PET concordance in Alzheimer disease versus frontotemporal dementia syndromes","volume":"84","author":"Bang","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0320","doi-asserted-by":"crossref","first-page":"P7.108","DOI":"10.1212\/WNL.84.14_supplement.P7.108","article-title":"Delayed-start analyses of solanezumab phase\u00a03\u00a0in mild Alzheimer's disease","volume":"84","author":"Doody","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0325","doi-asserted-by":"crossref","first-page":"P2.013","DOI":"10.1212\/WNL.84.14_supplement.P2.013","article-title":"Clinical characteristics of elderly patients with amyotrophic lateral sclerosis","volume":"84","author":"Nussbaum","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0330","doi-asserted-by":"crossref","first-page":"I8-1B","DOI":"10.1212\/WNL.84.14_supplement.I8-1B","volume":"84","author":"Brooks","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0335","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ana.22485","article-title":"Gain of function Nav1.7\u00a0mutations in idiopathic small fiber neuropathy","volume":"71","author":"Faber","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2015.04.005_bib0340","doi-asserted-by":"crossref","first-page":"P2.022","DOI":"10.1212\/WNL.84.14_supplement.P2.022","article-title":"The enlarging spectrum of Nav1.7\u00a0mutations associated with neurological pain syndromes","volume":"84","author":"Salhi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0345","doi-asserted-by":"crossref","first-page":"P2.002","DOI":"10.1212\/WNL.84.14_supplement.P2.002","article-title":"Peripheral nerve lymphoma: clinical, electrophysiological, radiographic and pathological findings","volume":"84","author":"Dyck","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0350","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neurol.2014.06.002","article-title":"Challenges in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"170","author":"Guimaraes-Costa","year":"2014","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2015.04.005_bib0355","doi-asserted-by":"crossref","first-page":"P7.081","DOI":"10.1212\/WNL.84.14_supplement.P7.081","article-title":"Prevalence and characteristics features of anti-human neurofascin 155\u00a0antibody-associated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"84","author":"Ogata","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0360","doi-asserted-by":"crossref","first-page":"P3.189","DOI":"10.1212\/WNL.84.14_supplement.P3.188","article-title":"Bortezomib-new option for aggressive chronic inflammatory demyelinating polyradiculoneuritis","volume":"84","author":"Pitarokoili","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0365","doi-asserted-by":"crossref","first-page":"S9.003","DOI":"10.1212\/WNL.84.14_supplement.S9.003","article-title":"Phase\u00a02\u00a0open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy","volume":"84","author":"Coelho","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2015.04.005_bib0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.msard.2015.01.005","article-title":"High doses of biotin in chronic progressive multiple sclerosis: a pilot study","volume":"4","author":"Sedel","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2015.04.005_bib0375","doi-asserted-by":"crossref","first-page":"PL2.002","DOI":"10.1212\/WNL.84.14_supplement.PL2.002","article-title":"Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase\u00a0III randomized double blind placebo controlled study","volume":"84","author":"Tourbah","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0380","doi-asserted-by":"crossref","first-page":"P7.202","DOI":"10.1212\/WNL.84.14_supplement.P7.202","article-title":"Efficacy analysis of the anti-LINGO-1\u00a0monoclonal antibody BIIB033\u00a0in acute optic neuritis: the Renew trial","volume":"84","author":"Cadavid","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0385","doi-asserted-by":"crossref","first-page":"P7.204","DOI":"10.1212\/WNL.84.14_supplement.P7.204","article-title":"BIIB033, anti-LINGO-1\u00a0antibody, for treatment of relapsing forms of multiple sclerosis: baseline data of the phase\u00a02\u00a0Synergy trial","volume":"84","author":"Cadavid","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0390","doi-asserted-by":"crossref","first-page":"S4.003","DOI":"10.1212\/WNL.84.14_supplement.S4.003","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing-remitting multiple sclerosis: primary results of the Decide study","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0395","doi-asserted-by":"crossref","first-page":"P7.198","DOI":"10.1212\/WNL.84.14_supplement.P7.198","article-title":"A randomized, double-blind, placebo-controlled trial of oral RPC1063\u00a0in adults with relapsing multiple sclerosis","volume":"84","author":"Comi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0400","doi-asserted-by":"crossref","first-page":"S4.007","DOI":"10.1212\/WNL.84.14_supplement.S4.007","article-title":"Durable effect of alemtuzumab on clinical outcomes in treatment-naive relapsing-remitting multiple sclerosis patients: 4-year follow-up of CARE-MS I","volume":"84","author":"Compston","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0405","doi-asserted-by":"crossref","first-page":"P7.276","DOI":"10.1212\/WNL.84.14_supplement.P7.276","article-title":"Durable effect of alemtuzumab on clinical outcomes in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: 4-year follow-up of CARE-MS\u00a0II","volume":"84","author":"Havrdova","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0410","doi-asserted-by":"crossref","first-page":"P7.246","DOI":"10.1212\/WNL.84.14_supplement.P7.246","article-title":"Durable effect of alemtuzumab on MRI activity in treatment-naive active relapsing-remitting multiple sclerosis patients: 4-year follow-up of CARE-MS I","volume":"84","author":"Arnold","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0415","doi-asserted-by":"crossref","first-page":"P7.249","DOI":"10.1212\/WNL.84.14_supplement.P7.249","article-title":"Durable effect of alemtuzumab on MRI outcomes in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: 4-year follow-up of CARE-MS\u00a0II","volume":"84","author":"Traboulsee","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0420","doi-asserted-by":"crossref","first-page":"P7.263","DOI":"10.1212\/WNL.84.14_supplement.P7.263","article-title":"Alemtuzumab slows brain volume loss over 4\u00a0years despite most relapsing-remitting multiple sclerosis patients not receiving treatment for 3\u00a0years","volume":"84","author":"Coles","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0425","doi-asserted-by":"crossref","first-page":"P7.272","DOI":"10.1212\/WNL.84.14_supplement.P7.272","article-title":"The efficacy of alemtuzumab is maintained in patients who develop thyroid adverse events","volume":"84","author":"Hunter","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0430","doi-asserted-by":"crossref","first-page":"P7.265","DOI":"10.1212\/WNL.84.14_supplement.P7.265","article-title":"Incidence of infections decreases over time in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis: 4-year follow-up of the CARE-MS studies","volume":"84","author":"Jung Henson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0435","doi-asserted-by":"crossref","first-page":"P3-251","DOI":"10.1212\/WNL.84.14_supplement.P3.251","article-title":"36-month Pangaea: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily practice","volume":"84","author":"Ziemssen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0440","doi-asserted-by":"crossref","first-page":"P3.249","DOI":"10.1212\/WNL.84.14_supplement.P3.249","article-title":"Efficacy and safety of fingolimod: the French Grand-Est cohort","volume":"84","author":"Tourbah","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0445","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1212\/WNL.84.14_supplement.P3.277","article-title":"Effect of fingolimod on no evidence of disease activity (NEDA-4) and safety in young adult patients with relapsing-remitting multiple sclerosis","volume":"84","author":"Ghezzi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0450","doi-asserted-by":"crossref","first-page":"S4.006","DOI":"10.1212\/WNL.84.14_supplement.S4.006","article-title":"Long-term safety of fingolimod: an interim analysis of the Longterms cohort","volume":"84","author":"Cohen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0455","doi-asserted-by":"crossref","first-page":"P7.234","DOI":"10.1212\/WNL.84.14_supplement.P7.234","article-title":"Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the Define, Confirm, and Endorse studies","volume":"84","author":"Bar-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0460","doi-asserted-by":"crossref","first-page":"P7.247","DOI":"10.1212\/WNL.84.14_supplement.P7.247","article-title":"Effect of delayed-release dimethyl fumarate on no evidence activity in newly diagnosed relapsing-remitting multiple sclerosis patients: an integrated analysis of the phase\u00a03\u00a0Define and Confirm studies","volume":"84","author":"Havrdova","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0465","doi-asserted-by":"crossref","first-page":"P3.241","DOI":"10.1212\/WNL.84.14_supplement.P3.241","article-title":"Safety and efficacy of dimethyl fumarate in patients with multiple sclerosis \u2013 Real world experience","volume":"84","author":"Chaves","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0470","doi-asserted-by":"crossref","first-page":"P3.240","DOI":"10.1212\/WNL.84.14_supplement.P3.240","article-title":"Dimethyl fumarate associated lymphopenia in clinical practice","volume":"84","author":"Longbrake","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0475","doi-asserted-by":"crossref","first-page":"P7.238","DOI":"10.1212\/WNL.84.14_supplement.P7.238","article-title":"Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience","volume":"84","author":"Li","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0480","doi-asserted-by":"crossref","first-page":"P3.245","DOI":"10.1212\/WNL.84.14_supplement.P3.245","article-title":"Assessing comparative outcomes from teriflunomide and dimethyl fumarate studies in relapsing MS: use of \u201cnumber needed to treat\u201d analysis","volume":"84","author":"Leist","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0485","doi-asserted-by":"crossref","first-page":"P7.274","DOI":"10.1212\/WNL.84.14_supplement.P7.274","article-title":"Efficacy of teriflunomide in early-stage MS: reanalysis of the TOPIC study using 2010\u00a0MacDonald diagnostic criteria","volume":"84","author":"Nelson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0490","doi-asserted-by":"crossref","first-page":"P7.268","DOI":"10.1212\/WNL.84.14_supplement.P7.268","article-title":"Pooled safety analyses from teriflunomide clinical studies","volume":"84","author":"Leist","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0495","doi-asserted-by":"crossref","first-page":"P7.223","DOI":"10.1212\/WNL.84.14_supplement.P7.223","article-title":"12-year clinical efficacy and safety data for teriflunomide: results from a phase\u00a02\u00a0extension study","volume":"84","author":"Kremenchutzky","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0500","doi-asserted-by":"crossref","first-page":"P4.031","DOI":"10.1212\/WNL.84.14_supplement.P4.031","article-title":"Anti-JC virus (JCV) antibody index differentiates risk of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients with no prior immunosuppressant (IS) use: an updated analysis","volume":"84","author":"Kueters","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ana.24250","article-title":"Testicular hypofunction and multiple sclerosis risk: a record-linkage study","volume":"76","author":"Pakpoor","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2015.04.005_bib0510","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1177\/1352458514527864","article-title":"Low testosterone is associated with disability in men with multiple sclerosis","volume":"20","author":"Bove","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2015.04.005_bib0515","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.nicl.2014.03.001","article-title":"Neuroprotective effects of testosterone treatment in men with multiple sclerosis","volume":"4","author":"Kurth","year":"2014","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.neurol.2015.04.005_bib0520","doi-asserted-by":"crossref","first-page":"S38.005","DOI":"10.1212\/WNL.84.14_supplement.S38.005","article-title":"The male 2D:4D digit ratio: a proxy for prenatal androgen exposure and a risk biomarker for multiple sclerosis","volume":"84","author":"Bove","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0525","doi-asserted-by":"crossref","first-page":"S38.006","DOI":"10.1212\/WNL.84.14_supplement.S38.006","article-title":"Association between low testosterone and brain atrophy in men multiple sclerosis","volume":"84","author":"Bove","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0530","doi-asserted-by":"crossref","first-page":"P2.208","DOI":"10.1212\/WNL.84.14_supplement.P2.208","article-title":"Lower 25-hydroxyvitamin\u00a0D levels in patients with clinically isolated syndrome compared to healthy controls are not associated with lower levels of bioavailable vitamin\u00a0D","volume":"84","author":"Behrens","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0535","doi-asserted-by":"crossref","first-page":"P4.014","DOI":"10.1212\/WNL.84.14_supplement.P4.014","article-title":"Vitamin\u00a0D as a predictor of functional deficits in multiple sclerosis","volume":"84","author":"Fitzgerald","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0540","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin\u00a0D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2015.04.005_bib0545","doi-asserted-by":"crossref","first-page":"S38.001","DOI":"10.1212\/WNL.84.14_supplement.S38.001","article-title":"High-dose vitamin\u00a0D supplementation reduces\u00a0IL-17-producing CD4+ T-cells and effector-memory CD4+ T-cells in multiple sclerosis patients","volume":"84","author":"Bhargava","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0550","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1756285612473513","article-title":"Contribution of vitamin\u00a0D insufficiency to the pathogenesis of multiple sclerosis","volume":"6","author":"Pierrot-Deseilligny","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2015.04.005_bib0555","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458513483889","article-title":"Childhood body mass index and multiple sclerosis risk: a long-term cohort study","volume":"19","author":"Munger","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2015.04.005_bib0560","doi-asserted-by":"crossref","DOI":"10.1177\/1352458514555787","article-title":"Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset","author":"Kavak","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2015.04.005_bib0565","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1352458514546785","article-title":"Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study","volume":"21","author":"Wesnes","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2015.04.005_bib0570","doi-asserted-by":"crossref","first-page":"P2.212","DOI":"10.1212\/WNL.84.14_supplement.P2.212","article-title":"The relationship between body mass index (BMI) and multiple sclerosis","volume":"84","author":"Ben-Zacharia","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0575","doi-asserted-by":"crossref","first-page":"S38.002","DOI":"10.1212\/WNL.84.14_supplement.S46.002","article-title":"Tobacco smoking and severity of neuromyelitis optica","volume":"84","author":"Kremer","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0580","doi-asserted-by":"crossref","first-page":"S38.003","DOI":"10.1212\/WNL.84.14_supplement.S38.003","article-title":"A case-control study of dietary salt intake and risk of pediatric multiple sclerosis (MS)","volume":"84","author":"MacDonald","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0585","doi-asserted-by":"crossref","first-page":"S38.004","DOI":"10.1212\/WNL.84.14_supplement.S38.004","article-title":"Sodium chloride-high diet promotes pro-inflammatory macrophage activation and aggravates central nervous system autoimmunity","volume":"84","author":"Klotz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2015.04.005_bib0590","doi-asserted-by":"crossref","first-page":"S45.004","DOI":"10.1212\/WNL.84.14_supplement.S45.004","article-title":"Greater consumption of coffee is associated with reduced odds of multiple Sclerosis","volume":"84","author":"Mowry","year":"2015","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378715007481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378715007481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T13:26:32Z","timestamp":1717939592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378715007481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":118,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0035378715007481"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2015.04.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Academy of Neurology, Washington, 18\u201325\u00a0avril\u00a02015","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2015.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}